Tamron Inc. 1Q Earnings Preview

A quarter that tests the ramp-up trajectory toward the FY2026 plan, while confirming acceleration of proprietary brand new product launches and sustained growth in automotive and medical segments, alongside US tariff risk and FX assumption validity

PublishedApril 28, 2026 at 15:30 GMT+9

Summary

Tamron posted a revenue and profit decline for FY2025/12, but for FY2026/12—the final year of its mid-term plan "Value Creation26 Ver.2.0"—the company guides for revenue of JPY 91B (+7.0%) and operating income of JPY 18.5B (+11.2%), marking a return to top- and bottom-line growth. Ver.2.0 was an upward revision announced in February 2025 after the company achieved all original mid-term plan targets ahead of schedule in FY2024. The revised plan targets revenue of JPY 95B, operating income of JPY 20.5B, ROE of 16%+, EBITDA margin of 24%+, and a total payout ratio of 60%, laying the groundwork for reaching "JPY 100B revenue company" status under the next mid-term plan. Growth engines include: multi-mount expansion into RF mount, Z mount, and others combined with 10+ annual proprietary brand new product launches (up from 6–7 previously); sustained growth in automotive lenses driven by expanding ADAS demand (targeting a JPY 12B business); expansion of the medical lens lineup (targeting JPY 3B by 2030); and a renewed growth push into FA and new domains (laser processing heads, etc.). In 1Q, investor attention will center on the ramp-up of these growth drivers, the impact of selective price increases implemented in April 2026, the effect of US reciprocal tariffs on the North American market, the divergence between the assumed FX rates (USD=JPY 148/EUR=JPY 175) and prevailing spot rates, and the progress of the Vietnam second factory start-up. The key question is whether Tamron can demonstrate earnings "quality" while sustaining its high OPM (19.6% → 20.3% guided), underpinned by its optical design capabilities and vertically integrated model.

Key Points for Next Quarter

Key Points & Focus	Implications
Revenue GrowthRegional revenue trends for proprietary brand interchangeable lenses	In the prior year, Japan, US, and India posted double-digit revenue growth, while Europe underperformed and China declined for the full year. 1Q results will gauge the degree of recovery across regions and the probability of achieving the +7.0% full-year plan and the Ver.2.0 mid-term target of JPY 95B revenue
New Product LaunchesPace of proprietary brand new product introductions	Ver.2.0 raised the target to 10+ per year (from 6 in prior year → 10+ in FY2026). Whether the 1Q launch schedule and rising new product mix can be confirmed
ProfitabilityOPM YoY trend	Prior year 19.6% → current year guidance 20.3%; Ver.2.0 targets 21.6% (20%+ range). 1Q will reveal the tug-of-war between April price revision benefits and rising raw material and labor costs
Automotive + MedicalRevenue and margin for Mobility & Healthcare segment	Prior year saw automotive lenses reach JPY 10B for the first time (sensing mix at 90%) and medical lenses exceed JPY 1B for the first time. Ver.2.0 targets automotive at JPY 12B and medical business commercialization; FY2026 plan calls for segment revenue of JPY 13.5B (+9.4%) with OPM of 18%+
FX + Tariff RiskDivergence between spot FX and full-year assumption (USD=JPY 148)	Ver.2.0 assumptions are USD=JPY 145/EUR=JPY 155, while FY2026 guidance assumes USD=JPY 148/EUR=JPY 175. Continued yen weakness could drive upside to the plan. Additionally, the impact of US reciprocal tariffs (10% on Japan) on North American sales warrants close monitoring
Mid-Term Plan KPIsProgress on ROE, EBITDA margin, and total payout ratio	Ver.2.0 targets ROE of 16%+, EBITDA margin of 24%+, and total payout ratio of 60%. Against prior year ROE of 14.0%, the key is whether FY2026 earnings recovery provides sufficient uplift. The annual dividend floor has already been raised to JPY 20 (approximately 1.6x the previous JPY 12.5)
FA + SurveillanceEnd of inventory adjustment cycle for FA/machine vision lenses	Prior year saw revenue decline due to customer inventory adjustments and delays in new camera module model development. FY2026 plan targets revenue of JPY 14.5B (+19.9%), a significant rebound. Focus is on confirming inventory normalization and product launches in new domains (SWIR/laser processing heads)
Supply ChainRamp-up of Vietnam second factory	Full-scale operations commenced in January 2025, with full utilization targeted by 2028. Group production capacity expanded 1.2x; China component sourcing ratio targeted to decline from 30% to below 20%. Monitor progress on tariff and geopolitical risk mitigation

Key Issues from Previous Results (FY2025/12 Full-Year)

Tamron's FY2025/12 results came in at revenue of JPY 85,071M (−3.8%) and operating income of JPY 16,638M (−13.4%), a top- and bottom-line decline. The mid-term plan "Value Creation26" saw all targets achieved ahead of schedule in the first year (FY2024/12), prompting an upward revision to Ver.2.0 (revenue JPY 95B / operating income JPY 20.5B / ROE 16%+) in February 2025. In year two (FY2025), a stronger yen against the dollar, lower photography-related OEM shipments, and rising costs converged to create a breather, but the company plans a return to growth in FY2026 as the final year, raising the question of whether it can prove the "quality" transformation of its business portfolio over the full year.

1. Photography-Related Business: Accelerating Multi-Mount Expansion and Proprietary Brand Recovery

Prior Year:
Photography-related segment revenue was JPY 60,643M (−6.5%), with operating income of JPY 15,630M (−13.7%). The proprietary brand held roughly flat YoY, while OEM declined due to market stagnation and weak sales of certain contracted models. A total of 13 models were launched across 2024 (7 models) and 2025 (6 models), including RF mount, accelerating mount expansion
This Quarter Confirmation:
FY2026 plan targets revenue of JPY 63B (+3.9%), operating income of JPY 17.2B (+10.0%), and OPM of 27.3%. Proprietary brand growth is planned through 10+ new product launches per year (target raised under Ver.2.0), recovery in European and Chinese markets, and continued US market growth. The impact of price revisions implemented in April 2026 is also a key confirmation item
Key Metrics:
Proprietary brand revenue YoY; photography segment margin (prior year 25.8% → guidance 27.3%; Ver.2.0 target 29%+)

2. Mobility & Healthcare Business: Sustainability of Growth After Automotive JPY 10B and Medical JPY 1B Milestones

Prior Year:
Segment revenue was JPY 12,336M (+8.9%), with operating income of JPY 2,699M (+9.0%). Automotive camera lenses exceeded JPY 10B for the first time, driven by expanding sensing applications (90% of mix) accompanying ADAS adoption. Medical lenses grew approximately 1.5x YoY, surpassing JPY 1B for the first time
This Quarter Confirmation:
FY2026 plan targets revenue of JPY 13.5B (+9.4%), operating income of JPY 2.5B (−7.4%), and OPM of 18.5%. While margins may dip due to medical segment incubation and element technology development for new domains, Ver.2.0 aims for automotive at JPY 12B and medical reaching JPY 3B by 2030 (surgical microscopes, fluorescence filter expansion)
Key Metrics:
Automotive lens revenue YoY; sensing application mix ratio; Mobility & Healthcare segment margin (prior year 21.9% → guidance 18.5%)

3. Surveillance & FA Business: Inventory Adjustment Cycle Completion and Camera Module Recovery

Prior Year:
Segment revenue was JPY 12,091M (−1.8%), but operating income rose to JPY 1,675M (+7.0%). FA/machine vision lenses declined due to customer inventory adjustments, and camera modules were impacted by delays in new model development. Surveillance camera lenses, however, grew on demand for higher resolution
This Quarter Confirmation:
FY2026 plan targets revenue of JPY 14.5B (+19.9%) and operating income of JPY 1.9B (+13.4%). Ver.2.0 outlines entry into new domains including SWIR, near-infrared light sources, multi-purpose cameras, and laser processing heads, targeting at least one new product launch in FY2026
Key Metrics:
FA/machine vision lens order trends; new domain product launch status; Surveillance & FA segment margin (prior year 13.9% → guidance 13.1%)

4. Cost Structure and OPM Recovery Potential

Prior Year:
OPM was 19.6% (down 2.1pt from 21.7% in prior year). Gross profit margin was 44.0% (prior year 44.5%), down 0.5pt. SG&A was JPY 20,779M (+2.9%), with R&D expenses up JPY 221M (to JPY 7,313M) and other SG&A up JPY 373M as key drivers. FX losses of JPY 439M (vs. JPY 158M in prior year) also weighed on profits
This Quarter Confirmation:
Full-year guided OPM is 20.3%; Ver.2.0 targets 21.6%. Cumulative R&D spend for FY2024–2026 is JPY 22.5B (1.4x the prior mid-term plan), with capex at JPY 17.5B (1.7x), reflecting aggressive forward investment. The focus is whether rising raw material and labor costs can be absorbed through April price revisions and cost reduction efforts
Key Metrics:
Gross profit margin YoY; SG&A ratio trend; FX rates (assumptions: USD=JPY 148, EUR=JPY 175 / Ver.2.0 assumptions: USD=JPY 145, EUR=JPY 155)

5. Capital Efficiency and Shareholder Returns: Final-Year Achievement of Mid-Term Plan

Prior Year:
ROE was 14.0% (prior year 19.0%); equity ratio was 81.0%. Annual dividend was JPY 36.25 (post-split equivalent), with a payout ratio of 49.8%. Share buybacks totaled JPY 4B (double the prior year's JPY 2B), bringing the cumulative FY2024–2025 total payout ratio above 60%. FY2026/12 annual dividend is guided at JPY 37.00
This Quarter Confirmation:
Ver.2.0 targets ROE of 16%+, EBITDA margin of 24%+, total payout ratio of ~60%, dividend payout ratio guideline of 40%, annual dividend floor of JPY 20 (1.6x the previous JPY 12.5), and a gradual reduction of equity ratio to ~75%. Achieving the FY2026 earnings growth plan is essential for ROE recovery toward the target level
Key Metrics:
ROE level (vs. 16%+ target); additional share buyback execution; maintenance of DOE floor of 3%+

Timely Disclosure & Industry Trends

2026/03/16
Notice Regarding Price Revisions for Select Products — Against the backdrop of US reciprocal tariffs and rising raw material, manufacturing, and logistics costs, Tamron will revise shipment prices and suggested retail prices for mirrorless camera lenses effective April 1, 2026. Expected to contribute to gross margin improvement Notice Regarding Price Revisions for Select Products
2026/02/09
Notice Regarding Publication of Third-Party Analyst Report — Commenced publication of a sponsored research report by Envaris Inc. Part of efforts to strengthen investor communication Notice Regarding Envaris Report Publication
2026/02/06
Long-Term Vision Refresh and "Value Creation26 Ver.2.0" Announcement — Under the vision "Capture, Measure, Connect: Creating Health for People and Nature," Tamron aims to evolve into a comprehensive optical and sensing solutions company addressing societal challenges through optics × sensing × data integration. Toward reaching JPY 100B revenue, the company established JPY 18B in strategic investment including Vietnam second factory operations, an M&A allocation of JPY 15B, and JPY 3B in open innovation investment Tamron Long-Term Vision Refresh

Previous Quarter Results (FY2025/12 Full-Year Actuals)

Tamron is a pure-play optical lens manufacturer centered on mirrorless camera interchangeable lenses, with multi-mount support across Sony E mount, Fujifilm X mount, Nikon Z mount, and Canon RF mount as a key differentiator. The mid-term plan "Value Creation26 Ver.2.0" (FY2024–2026) targets revenue of JPY 95B, operating income of JPY 20.5B, EBITDA margin of 24%+, ROE of 16%+, and a total payout ratio of ~60%, bridging to JPY 100B revenue under the next mid-term plan. All original mid-term plan targets were achieved ahead of schedule in the first year (FY2024/12), prompting the upward revision in February 2025. In FY2025/12, revenue and profits declined due to yen appreciation against the dollar, lower OEM shipments, and rising costs, but automotive lenses exceeded JPY 10B and medical lenses exceeded JPY 1B for the first time, evidencing continued expansion of the non-camera business portfolio.

Item	Amount	YoY	vs. Company Plan	Remarks
Revenue	JPY 85,071M	−3.8%	−2.2%	Photography-related −6.5%; Mobility & Healthcare +8.9%
Operating Income	JPY 16,638M	−13.4%	−7.6%	OPM 19.6% (prior year 21.7%)
Recurring Profit	JPY 16,699M	−13.5%	−8.2%	FX losses of JPY 439M weighed on results
Net Income	JPY 11,761M	−19.0%	−13.3%	Net investment securities gains/losses: −JPY 247M
EPS	JPY 72.79	−17.2%	-	Avg. shares outstanding: 161,588K

FY2026/12 Company Guidance: Revenue JPY 91,000M (+7.0%), Operating Income JPY 18,500M (+11.2%), Recurring Profit JPY 18,500M (+10.8%), Net Income JPY 13,690M (+16.4%), EPS JPY 84.91. FX assumptions: USD=JPY 148, EUR=JPY 175 (Ver.2.0 assumptions: USD=JPY 145, EUR=JPY 155)